Controller

Exosens supports the accelerating deployment of next-generation nuclear technologies in the U.S. October 08, 2026 12:00 ET | Source: Exosens * Key milestones achieved under the U.S. Department of Energy's Reactor Pilot Program highlight the accelerating deployment of next-generation nuclear technologies * Exosens' advanced neutron flux monitoring detectors supported successful criticality demonstrations by Antares Nuclear and Valar Atomics, underscoring the relevance of its technologies across Small Modular Reactor (SMR) applications * These achievements are expected to translate into near-term pre-series production orders and support long-term demand for Exosens' nuclear instrumentation solutions Press release, Mérignac (France), 8 October 2026 - Exosens (EXENS; FR001400Q9V2), a high-tech company focused on providing mission- and performance-critical amplification, detection and imaging technologies, today announces its contribution to two successful criticality demonstrations for next-generation nuclear reactors under the U.S. Department of Energy's Reactor Pilot Program. In August 2025, the program initially selected 11 advanced reactor projects with the goal of bringing at least three reactor designs to criticality by 4 July 2026. The program exceeded that objective, with four projects reaching this milestone by the deadline. These achievements mark a decisive step towards the commercial deployment of next-generation nuclear technologies on an accelerated timeline in the United States, particularly across SMR applications. Against this backdrop, Exosens supplied high-performance neutron detectors and related technical expertise to Antares Nuclear and Valar Atomics, the developers behind the first two reactor designs to reach criticality as part of the DOE's Reactor Pilot Program. Integrated into safety-related neutron flux monitoring systems, these advanced detectors provide the measurements required to monitor reactor power and track the approach to criticality during start-up and testing. These achievements are expected to translate into pre-series production orders in the near term and support long-term demand for Exosens' nuclear instrumentation solutions across the U.S. market. "The move towards commercial deployment of next-generation nuclear technologies is accelerating in the United States, supported by increasing demand for reliable, carbon-free power, notably to meet the unprecedented energy requirements of AI-enabled data centers. This momentum is reinforcing investment in SMR technologies and driving demand for high-performance instrumentation designed for demanding nuclear environments, creating significant long-term growth opportunities for Exosens. Already providing advanced nuclear detection solutions for seven SMR-related projects across the United States and Europe, Exosens leverages its differentiated technologies, deep nuclear expertise and industrial capabilities to address these needs and support the long-term development of the SMR market," said Jérôme Cerisier, CEO of Exosens. "Achieving criticality is a defining milestone in next-generation reactor development. The progress made by Antares Nuclear and Valar Atomics demonstrates the pace of innovation across the U.S. nuclear industry. We are proud to have supported these successful demonstrations through Exosens' advanced neutron flux monitoring technologies, and look forward to helping reactor developers as they move from first-of-a-kind testing towards safe, reliable commercial deployment," said Cyril Barre, Nuclear Instrumentation Director at Exosens. Financial calendar * 27/10/2026: 9M 2026 revenue and adjusted gross margin (before market opening). * 22/02/2027: FY 2026 results (before market opening). About Exosens Exosens is a high-tech company with more than 85 years of experience in the innovation, development, manufacturing and sale of high-end electro-optical technologies in the fields of amplification, detection and imaging. Today, it offers its customers detectors and imaging solutions such as digital cameras, ion, electron, neutron and gamma-ray detectors as well as image intensifier tubes. This enables Exosens to address complex challenges in extremely demanding environments by providing its customers with tailor-made solutions. Thanks to its sustained investment, Exosens is internationally recognized as a major innovator in optoelectronics, with production and R&D activities carried out at 13 sites across Europe and North America and more than 2,000 employees. Exosens is listed on compartment A of the regulated market of Euronext Paris (Ticker: EXENS - ISIN: FR001400Q9V2). Exosens is a member of the Euronext Tech Leaders segment and is also included in several indices, including SBF 120, CAC All-Tradable, CAC Mid 60, FTSE Total Cap and MSCI France Small Cap. For more information: www.exosens.com. Investor Relations Media Relations

Antares, Centrus sign multi-year HALEU contract. Friday, 18 September 2026 Pre-payments under the contract will support Centrus's ongoing expansion of its uranium enrichment capacity, with deliveries of high-assay low-enriched uranium (HALEU) to support Antares' advanced reactor projects, including for space and national security missions, to begin by the end of the decade. Antares is developing modular, transportable reactors, fuelled using TRISO (tri-structural isotropic) HALEU fuel. The company's Antares 0 achieved criticality in June, becoming the first reactor under the Department of Energy's Reactor Pilot Program to achieve criticality by the deadline of 4 July set in 2025 by US President Donald Trump. The fuel for the criticality demonstration was provided by BWX Technologies, Inc. "Fuel supply is one of the practical questions every advanced reactor developer has to answer," said Antares co-founder and CEO Jordan Bramble. "This contract gives Antares a reliable, US-origin source of HALEU for the reactors we're deploying for a wide variety of defence and space customers." Centrus is already producing HALEU at its American Centrifuge Plant in Piketon, Ohio, and last year launched a multi-billion-dollar expansion including large-scale production of HALEU as well as the low-enriched uranium used in today's operating nuclear power plants. The contract is a sign that demand for HALEU is real and is accelerating, Centrus President and CEO Amir Vexler said. "Binding orders from Antares and others are supporting our expansion to commercial-scale production - an expansion that is now well under way." In August, Antares was one of five microreactor developers selected by the US Department of the Army for deployment at five Department of War installations, under the Janus programme - the next-generation nuclear power programme - which, under an Executive Order signed by Trump in May 2025, aims for operation of an Army-regulated nuclear reactor at a domestic military installation no later than 30 September 2028. Antares is to construct and operate nuclear microreactor power at Fort Bragg, North Carolina, under the programme. It has also been selected for deployment at Joint Base San Antonio, Texas, under the US Air Force's Advanced Nuclear Power for Installations programme, and is a recipient of a US Space Force Strategic Breakthrough award to demonstrate a space reactor. Certain nuclear applications in the USA, particularly those related to national security missions, require a supply of so-called unobligated enriched uranium: uranium that is free of peaceful use obligations that apply to uranium and certain technologies imported into the US under international agreements. Centrus's enrichment technology and manufacturing supply chain are of US origin, and its AC100 centrifuge design is the only deployment-ready enrichment technology capable of 'unobligated' enrichment, so the arrangement can provide Antares with fuel that could be used for a variety of national security applications. [Urenco's Magnus Mori and Antares' Tom Mancinelli pictured at World Nuclear Symposium (Image: World Nuclear Association)] Earlier this year, Antares signed a multi-year contract for the supply of HALEU with Urenco, to be produced at Urenco's HALEU enrichment facility in the UK. That facility, at the Capenhurst site in north-west England, is already being built with funding support from the UK government and is scheduled to come online in 2031. A diversity of supply sources is important to avoid over-reliance on single suppliers, Antares Head of Federal Strategy and Policy Tom Mancinelli said at a side event at World Nuclear Symposium 2026 last week. "Certainly we recognise how important it is that strategic inputs like fuel don't have any dependencies or vulnerabilities to foreign suppliers who could immediately cut something off," Mancinelli said in the event's Knowledge Zone. "It's simple to me. It comes down to supply and demand and where we have, in the case of Urenco, a demonstrated track record in enrichment - I welcome that sort of partnership, including if it's coming from Capenhurst or from (Urenco USA's enrichment plant in) New Mexico. We want to see an increase in supply from trusted Western partners who share our values, and so we think Urenco is a great fit for Antares."